[1] Janka G. Hemophagocytic lymphohistiocytosis: when the immune system runs amok[J]. Klin Padiatr, 2009;221:278-85.
[2] Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis[J]. Annu Rev Med, 2012;63:233-46.
[3] Trottestam H, Horne A, Arico M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol[J]. Blood, 2011;118:4577-84.
[4] Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis[J]. Mayo Clin Proc, 2014;89:484-92.
[5] Tseng YT, Sheng WH, Lin BH, et al. Causes, clinical symptoms, and outcomes of infectious diseases associated with hemophagocytic lymphohistiocytosis in Taiwanese adults[J]. J Microbiol Immunol Infect, 2011;44:191-7.
[6] Fukaya S, Yasuda S, Hashimoto T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases[J]. Rheumatology (Oxford), 2008;47:1686-91.
[7] Lambotte O, Khellaf M, Harmouche H, et al. Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome[J]. Medicine (Baltimore), 2006;85:169-82.
[8] Machaczka M, Vaktnas J, Klimkowska M, Hagglund H. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center[J]. Leuk Lymphoma, 2011;52:613-9.
[9] Krishnan B, Morgan GJ. Non-Hodgkin lymphoma secondary to cancer chemotherapy[J]. Cancer Epidemiol Biomarkers Prev, 2007;16:377-80.
[10] Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide[J]. J Clin Oncol, 2005;23:4179-91.
[11] Wolff AC, Blackford AL, Visvanathan K, et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience[J]. J Clin Oncol, 2015;33:340-8.
[12] Bernard-Marty C, Mano M, Paesmans M, et al. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients[J]. Ann Oncol, 2003;14:693-8.
[13] Rossi D, Sarti D, Malerba L, et al. Secondary bone marrow malignancies after adjuvant chemotherapy for breast cancer: a report of 2 cases and a review of the literature[J]. Tumori, 2016;102.
[14] Zhang B, Zhang X, Li M, Kong L, Deng X, Yu J. How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy[J]. Cancer Biol Ther, 2016;17:125-8.
[15] Early Breast Cancer Trialists' Collaborative G, Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials[J]. Lancet, 2012;379:432-44.
[16] Park MJ, Park YH, Ahn HJ, et al. Secondary hematological malignancies after breast cancer chemotherapy[J]. Leuk Lymphoma, 2005;46:1183-8.
[17] Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis[J]. Am J Hematol, 2015;90:220-4.
[18] Tamamyan GN, Kantarjian HM, Ning J, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes[J]. Cancer, 2016;122:2857-66.
[19] Arca M, Fardet L, Galicier L, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide[J]. Br J Haematol, 2015;168:63-8.
[20] Machaczka M, Nahi H, Karbach H, Klimkowska M, Hagglund H. Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation[J]. Med Oncol, 2012;29:1231-6.
[21] Han AR, Lee HR, Park BB, et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome[J]. Ann Hematol, 2007;86:493-8.